NCT06005428

Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

A Phase 2A, Investigator & Subject Blinded, Sponsor Unblinded, Placebo-Controlled, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Cardurion Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when administered as single oral doses to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The study will have 2 cohorts in which participants with CPVT will participate in a 3-period, randomized 2-sequence study. Each participant will receive 2 different doses of CRD-4730 and 1 dose of matching placebo, with each study drug administered as a single dose.

Conditions

• CPVT1
• Heart Defects, Congenital
• Heart Diseases
• Ventricular Tachycardia

Interventions

Type	Name	Description
DRUG	CRD-4730	Oral CRD-4730 in capsule form
DRUG	Placebo	Placebo to match CRD-4730 in capsule form

Timeline

• Start date: 2023-11-07
• Primary completion: 2025-05-31
• Completion: 2025-05-31
• First posted: 2023-08-22
• Last updated: 2025-07-14

Locations

11 sites across 4 countries: United States, Canada, France, Italy

Regulatory

• FDA-regulated drug study